Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine
BackgroundAtypical chronic myeloid leukemia (aCML) is a BCR::ABL1 negative myelodysplastic/myeloproliferative neoplasm with poor overall survival. Some patients can be treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) from suitable donors. The effectiveness of decitabine or a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1353818/full |
| _version_ | 1827356669779116032 |
|---|---|
| author | Lu Liu Xiaofeng Song Wenhao Dong Zhao Li Dongmei Guo |
| author_facet | Lu Liu Xiaofeng Song Wenhao Dong Zhao Li Dongmei Guo |
| author_sort | Lu Liu |
| collection | DOAJ |
| description | BackgroundAtypical chronic myeloid leukemia (aCML) is a BCR::ABL1 negative myelodysplastic/myeloproliferative neoplasm with poor overall survival. Some patients can be treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) from suitable donors. The effectiveness of decitabine or azacitidine (AZA) has recently been reported; however, their combined efficacy with selinexor has not yet been reported.Case descriptionIn this study, we report the case of a patient with aCML who was successfully treated with selinexor combined with AZA. A 67-year-old man with a history of gastric mucosa-associated lymphoid tissue (MALT) lymphoma was admitted to the hospital with fatigue and emaciation. He was diagnosed with aCML and no longer responded to decitabine treatment after undergoing seven cycles. The patient was subsequently administered hydroxyurea (HU), selinexor, and AZA. After four courses of combination therapy, his blood cell counts improved; he no longer required transfusions and was able to discontinue HU. The patient continued receiving selinexor and AZA without severe complications. This case is the first to show that combinatorial selinexor and AZA therapy can effectively treat aCML.ConclusionOur case sheds light on the importance of selinexor and AZA combined therapy in the exploration of new treatment strategies for aCML. Moreover, this treatment approach offers the possibility of bridging with allo-HSCT. |
| first_indexed | 2024-03-08T05:13:18Z |
| format | Article |
| id | doaj.art-8d1e3cb09b904d7b9ab0dee215681b38 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-08T05:13:18Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8d1e3cb09b904d7b9ab0dee215681b382024-02-07T05:19:47ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-02-011410.3389/fonc.2024.13538181353818Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabineLu Liu0Xiaofeng Song1Wenhao Dong2Zhao Li3Dongmei Guo4Department of Hematology, Qilu Hospital (Qingdao) of Shandong University, Qingdao, ChinaDepartment of Hand and Foot Surgery, Qilu Hospital (Qingdao) of Shandong University, Qingdao, ChinaDepartment of Hematology, Qilu Hospital (Qingdao) of Shandong University, Qingdao, ChinaDepartment of Hematology, Qilu Hospital (Qingdao) of Shandong University, Qingdao, ChinaDepartment of Hematology, Qilu Hospital (Qingdao) of Shandong University, Qingdao, ChinaBackgroundAtypical chronic myeloid leukemia (aCML) is a BCR::ABL1 negative myelodysplastic/myeloproliferative neoplasm with poor overall survival. Some patients can be treated by allogeneic hematopoietic stem cell transplantation (allo-HSCT) from suitable donors. The effectiveness of decitabine or azacitidine (AZA) has recently been reported; however, their combined efficacy with selinexor has not yet been reported.Case descriptionIn this study, we report the case of a patient with aCML who was successfully treated with selinexor combined with AZA. A 67-year-old man with a history of gastric mucosa-associated lymphoid tissue (MALT) lymphoma was admitted to the hospital with fatigue and emaciation. He was diagnosed with aCML and no longer responded to decitabine treatment after undergoing seven cycles. The patient was subsequently administered hydroxyurea (HU), selinexor, and AZA. After four courses of combination therapy, his blood cell counts improved; he no longer required transfusions and was able to discontinue HU. The patient continued receiving selinexor and AZA without severe complications. This case is the first to show that combinatorial selinexor and AZA therapy can effectively treat aCML.ConclusionOur case sheds light on the importance of selinexor and AZA combined therapy in the exploration of new treatment strategies for aCML. Moreover, this treatment approach offers the possibility of bridging with allo-HSCT.https://www.frontiersin.org/articles/10.3389/fonc.2024.1353818/fullatypical chronic myeloid leukemiaselinexorazacitidinecase reportsynergism |
| spellingShingle | Lu Liu Xiaofeng Song Wenhao Dong Zhao Li Dongmei Guo Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine Frontiers in Oncology atypical chronic myeloid leukemia selinexor azacitidine case report synergism |
| title | Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine |
| title_full | Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine |
| title_fullStr | Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine |
| title_full_unstemmed | Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine |
| title_short | Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine |
| title_sort | case report safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine |
| topic | atypical chronic myeloid leukemia selinexor azacitidine case report synergism |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1353818/full |
| work_keys_str_mv | AT luliu casereportsafetyandefficacyofsynergistictreatmentusingselinexorandazacitidineinpatientswithatypicalchronicmyeloidleukemiawithresistancetodecitabine AT xiaofengsong casereportsafetyandefficacyofsynergistictreatmentusingselinexorandazacitidineinpatientswithatypicalchronicmyeloidleukemiawithresistancetodecitabine AT wenhaodong casereportsafetyandefficacyofsynergistictreatmentusingselinexorandazacitidineinpatientswithatypicalchronicmyeloidleukemiawithresistancetodecitabine AT zhaoli casereportsafetyandefficacyofsynergistictreatmentusingselinexorandazacitidineinpatientswithatypicalchronicmyeloidleukemiawithresistancetodecitabine AT dongmeiguo casereportsafetyandefficacyofsynergistictreatmentusingselinexorandazacitidineinpatientswithatypicalchronicmyeloidleukemiawithresistancetodecitabine |